skip to main content

Rheumatoid arthritis biologic therapy — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

HardInflammatory ArthritisRheumatoid arthritis biologic therapySCE Rheumatology

A patient with rheumatoid arthritis has high disease activity despite optimised methotrexate. Several NICE-approved biologic options are available. Which factor should drive the choice rather than selecting one agent arbitrarily?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Comorbidity, infection risk, route, prior therapy and patient preference

When multiple commissioned options are clinically suitable, selection should integrate comorbidity, infection and malignancy history, pregnancy plans, route, dosing, prior response and patient preference. The stem must supply a discriminating feature before one named biologic can be the single best answer.

Reference: https://www.nice.org.uk/guidance/conditions-and-diseases/musculoskeletal-conditions